A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

NCT 05381909

Brief Summary

This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.

Intervention / Treatment 

  • Drug: BGB-24714
  • Drug: Paclitaxel
  • Drug: Carboplatin
  • Drug: Docetaxel

Inclusion Criteria

  1. Participants must sign a written informed consent form (ICF); and agree to comply with study requirement
  2. Phase 1a (Dose Escalation):Part A, A-CN, and B: Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumor previously treated with standard systemic therapy or for whom treatment is not available or not tolerated Note: Only Chinese participants will be eligible for Part A-CN.Part C: Participant has histologically or cytologically confirmed, locally advanced, unresectable Stage III Non-small cell lung cancer (NSCLC) suitable for definitive chemoradiotherapy (CRT)Part D: Participant with locally advanced, histologically confirmed inoperable esophageal squamous cell carcinoma (ESCC) suitable for definitive CRTPhase 1b (Dose Expansion): Participants with histologically or cytologically confirmed solid tumors of selected types previously treated with standard therapy.
  3. Participants must be able to provide formalin-fixed paraffin embedded (FFPE) tumor tissue sample.
  4. Phase 1a Part A, A-CN, B and Phase 1b: ≥ 1 measurable lesion per Response evaluation criteria in solid tumors (RECIST) v1.1
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.